Text Size

Antidiabetic Properties of Rose Hip

This study has been completed.
Sponsor:
Information provided by:
Lund University
ClinicalTrials.gov Identifier:
NCT01316016
First received: March 15, 2011
Last updated: NA
Last verified: February 2011
History: No changes posted
  Purpose

The purpose of this study is to determine whether daily intake of a drink containing rose hip powder reduces risk markers of type diabetes and cardiovascular disease.


Condition Intervention
Obesity
 Dietary Supplement: Rose hip

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Effects of Rose Hip Intake on Risk Markers of Type 2 Diabetes and Cardiovascular Disease: a Randomized Double-blind Cross-over Investigation in Obese Persons

Resource links provided by NLM:

MedlinePlus related topics: Diabetes Obesity
U.S. FDA Resources

Further study details as provided by Lund University:

Enrollment: 31
Study Start Date: April 2009
Study Completion Date: January 2011
Primary Completion Date: February 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Rose hip Dietary Supplement: Rose hip
40 g of rose hip powder daily for 6 weeks.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • BMI > 30
  • willingness to participate in the study
  • willingness to comply with the daily intake of drinks and the recommended energy intake during the course of the study

Exclusion Criteria:

  • diabetes
  • previous or ongoing insulin treatment
  • abnormal thyroid status
  • abnormal liver status
  • abnormal kidney status
  • known gastrointestinal disorder
  • pregnancy
  • suspected allergy to ingredients of the drinks
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01316016

Locations
Sweden
Endocrinology Clinic, Lund University Hospital
Lund, Sweden, SE-22185
Sponsors and Collaborators
Lund University
Investigators
Study Chair: Per Katzman, MD/PhD Lund University
  More Information

Additional Information:
Related Info  This link exits the ClinicalTrials.gov site

Publications:

Responsible Party: Cecilia Holm, Lund University
ClinicalTrials.gov Identifier: NCT01316016     History of Changes
Other Study ID Numbers: LUAFC002
Study First Received: March 15, 2011
Last Updated: March 15, 2011
Health Authority: Sweden: Regional Ethical Review Board

Keywords provided by Lund University:
obesity
glucose intolerance
cholesterol
blood pressure

Additional relevant MeSH terms:
Cardiovascular Diseases
Obesity
Overnutrition
Nutrition Disorders
 Overweight
Body Weight
Signs and Symptoms

ClinicalTrials.gov processed this record on May 23, 2013